Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

Kidney International

Volumn 44, Issue 5, 1993, Pages 1124-1129

  Thomas, Mark E ^a   Harris, Kevin P G ^b   Ramaswamy, C ^b   Hattersley, Jane M ^b   Wheeler, David C ^b   Varghese, Zac ^b   Williams, John D ^b   Walls, John ^b   Moorhead, John F ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INULIN; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; LOVASTATIN; MALE; MIDDLE AGE; NEPHROTIC SYNDROME; PLACEBOS; PROTEINURIA; SIMVASTATIN; TRIGLYCERIDES;

EID: 0027482701     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1993.358     Document Type: Article

References (35)

1. APPEL GB, BLUM CB, CHIEN S, KUNIS CL, APPEL AS: The hyperlipidemia of the nephrotic syndrome. N Engl J Med 312:1544-1548, 1985
2. JOVEN J, VILLABONA C, VILELLA E, MASANA L, ALBERTI R, VALLES M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
3. VEGA GL, GRUNDY SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33:1160-1168, 1988
4. WARWICK GL, CASLAKE MJ, BOULTON-JONES JM, DAGEN M, PACKARD CJ, SHEPHERD J: Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 39:187-192, 1990
5. WARWICK GL, PACKARD CJ, DEMANT T, BEDFORD DK, BOULTON-JONES JM, SHEPHERD J: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 40:129-138, 1991
6. ORDONEZ JD, HIATT R, KILLEBREW E, FIREMAN B: The risk of coronary artery disease among patients with the nephrotic syndrome. (abstract) Kidney Int 37:243, 1990
7. MOORHEAD JF, CHAN MK, EL-NAHAS M, VARGHESE Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1312, 1982
8. ILLINGWORTH DR: Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 41:151-160, 1991
9. NATIONAL CHOLESTEROL EDUCATION PROGRAM: Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-69, 1988
10. THOMAS ME, FREESTONE AL, VARGHESE Z, PERSAUD JW, MOORHEAD JF: Lipoprotein (a) in proteinuric patients. Nephrol Dial Transplant 7:597-601, 1992
11. COLE RB, GIANGIACOMO J, INGLEFINGER JR, ROBSON AM: Measurement of renal function without urine collection. A critical evaluation of the constant-infusion technic for the determination of inulin and para-aminohippurate. N Engl J Med 287:1109-1114, 1972
12. ROE JH, EPSTEIN JH, GOLDSTEIN NP: A photometric method for the determination of inulin in plasma and urine. J Biol Chem 178:839-845, 1949
13. KAYSEN GA: Hyperlipidemia of the nephrotic syndrome. Kidney Int 39 (Suppl 31):S8-S15, 1991
14. MALLICK NP, SHORT CD: The nephrotic syndrome and ischaemic heart disease. Nephron 27:54-57, 1981
15. WASS V, CAMERON JS: Cardiovascular disease and the nephrotic syndrome: The other side of the coin. Nephron 27:58-61, 1981
16. COLLINS R, KEECH A, PETO R, SLEIGHT P, KJEKSHUS J, WILHELMSEN L, MACMAHON S, SHAW J, SIMES J, BRAUNWALD E, BURING J, HENNEKENS C, PFEFFER M, SACKS F, PROBSTFIELD J, YUSUF S, DOWNS JR, GOTTO A, COBBE S, FORD I, SHEPHERD J: Cholesterol and total mortality: Need for larger trials. Br Med J 304:1689, 1992
17. DIAMOND JR, KARNOVSKY MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 33:917-924, 1988
18. DIAMOND JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 39 (Suppl 31):S29-S34, 1991
19. KEANE WF, MULCAHY WS, KASISKE BL, KIM Y, O'DONNELL MP: Hyperlipidemia and progressive renal disease. Kidney Int 39 (Suppl 31):S41-S48, 1991
20. BRIDGMAN JF, ROSEN SM, THORP JM: Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. Lancet 2:506-509, 1972
21. TOBERT JA: Efficacy and long-term adverse effect pattern of Lovastatin. Am J Cardiol 62:28J-34J, 1988
22. RABELINK AJ, HENE RJ, ERKELENS DW, JOLES JA, KOOMANS HA: Effects of Simvastatin and Cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 2:1335-1338, 1988
23. GOLPER TA, ILLINGWORTH DR, MORRIS CD, BENNETT WM: Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 13:312-320, 1989
24. KASISKE BL, VELOSA JA, HALSTENSON CE, LA BELLE P, LANGENDORFER A, KEANE WF: The effects of Lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 15:8-15, 1990
25. WARWICK GL, PACKARD CJ, MURRAY L, GRIERSON D, STEWART JP, SHEPHERD J, BOULTON-JONES JM: Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome. Clin Sci 82:701-708, 1992
26. CHAN PCK, ROBINSON JD, YEUNG WC, CHENG IKP, YEUNG HWD, TSANG MTS: Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7:93-99, 1992
27. BRADFORD RH, SHEAR CL, CHREMOS AN, DUJOVNE CA, DOWNTON M, FRANKLIN FA, GOULD AL, HESNEY M, HIGGINS J, HURLEY DP, LANGENDORFER A, NASH DT, POOL JL, SCHNAPER H: Expanded clinical evaluation of Lovastatin (EXCEL) study results. Arch Intern Med 151:43-49, 1991
28. DESLYPERE JP, DELANGHE J, VERMEULEN A: Proteinuria as a complication of Simvastatin treatment. Lancet 336:1453, 1990
29. LA BELLE P, MANTEL G: Simvastatin and proteinuria. Lancet 337:864, 1991
30. RABELINK AJ, HENE RJ, ERKELENS DW, KOOMANS HA: Partial remission of nephrotic syndrome in patients on long-term simvastatin. Lancet 1:1045-1046, 1990
31. LIPID RESEARCH CLINICS PROGRAM: The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984
32. FRICK MH, ELO O, HAAPA K, HEINONEN OP, HEINSALMI P, HELO P, HUTTUNEN JK, KAITANIEMI P, KOSKINEN P, MANNINEN V, MAENPAA H, MALKONEN M, MANTTARI M, NOROLA S, PASTERNACK A, PIKKARAINEN J, ROMO M, SJOBLOM T, NIKKILA EA: Helsinki heart study: Primary-prevention trial with Gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
33. BROWN G, ALBERS JJ, FISHER LD, SCHAEFER SM, LIN JT, KAPLAN C, ZHAO XQ, BISSON BD, FITZPATRICK VF, DODGE HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289-1298, 1990
34. POCOCK SJ: The size of a clinical trial, in Clinical Trials. A Practical Approach, Chichester, John Wiley & Sons, 1983, p. 123
35. LOCATELLI F, ALBERTI D, GRAZIANI G, BUCCIANTI G, REDAELLI B, GIANGRANDE A, AND THE NORTHERN ITALIAN COOPERATIVE STUDY GROUP: Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet 337:1299-1304, 1991